Wound Management Technologies Adds CFO and Director of Research and Developmentadmin
ADDISON, TX / ACCESSWIRE / March 17, 2014 / Wound Management Technologies, Inc., (OTCQB: WNDM) has engaged Mr. Darren Stine as the Company’s new Chief Financial Officer and Mr. Barry Constantine has agreed to expand his role within the Company as its new Director of Research and Development.
“We are excited to continue to grow our executive team with top caliber people,” stated Robert Lutz, Jr., Chairman and CEO. “We are seeing very positive results in the execution of our strategic plan and we have now fulfilled our need for a strong financial leader and a seasoned R&D leader with the addition of Darren Stine and the expanded role of Barry Constantine. This is a very exciting step forward for us.”
Darren Stine, CFO, brings over twenty years of progressive and broad experience developing, managing, and leading finance and accounting functions for companies. In addition to holding senior management positions at JPO Management, County Fresh, Aventine Renewable Entergy, and EcoProduct Solution, he has also owned a successful tax and accounting consulting firm. Darren’s strengths include in-depth understanding of Federal and State Tax, SOX, Treasury, SEC Reporting, Auditing, and Finance & Accounting processes. He has been instrumental in strategically aligning companies to meet and exceed owner/shareholders expectation and in streamlining corporate procedures.
Barry Constantine, Director of R&D, has more than 30 years of healthcare industry experience including senior positions with Johnson & Johnson, Bristol Myers Squibb, Sherwood Medical and Integra LifeSciences. His professional skill set includes corporate and division level leadership of product development and project management for early stage and mature organizations. Barry has extensive experience in the areas of pharmaceuticals, tissue engineering, wound healing and skin care and has significant experience in business development and market research. He is very active in regulatory affairs including direct communications with the FDA, medical device submissions of all classes, combination products, pharmaceuticals, follow-on biologics (biosimilars) and Quality System Regulations. Barry continues to work with the Wound Care Innovations Subsidiary’s CellerateRX(R) product line and he is also the co-inventor of the Resorbable Orthopedic Products’ Subsidiary’s resorbable hemostat.
About Wound Management
Wound Management Technologies, Inc., is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management’s primary focus is the distribution of its unique, patented collagen product, CellerateRX(R), which is FDA cleared and reimbursable under Medicare Part B. Wound Management has other advanced biotech products in development including a patented resorbable hemostat that is in the late stages of development. More information can be found on the company’s web sites: http://www.wmgtech.com/ and http://www.celleraterx.com/ .
Safe Harbor Statement
The statements in the press release that relate to the company’s expectations with regard to the future impact on the company’s results from new products in development and any other statements not constituting historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company’s actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company’s operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s SEC filings, which could cause the company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
Wound Management Technologies, Inc.
16633 Dallas Parkway, Suite 250
Addison, TX 75001
SOURCE: Wound Management Technologies, Inc.
Posted: March 17th, 2014 under ACCESSWIRE.